secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProPhase Labs, Inc. (PRPH)
CIK:        0000868278
Form:       8-K
Filed at:   2022-12-20T23:59:59+00:00
Accession:  0001493152-22-035948
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProPhase Labs to acquire Stella Diagnostics' BE-Smart esophageal cancer test for approx $4.5M
--------------------------------------------------------------------------------

- Total consideration ~$4.5M ($3.5M cash + 100k shares of PRPH common stock); up to $2M additional PRPH shares upon commercial milestone.
- BE-Smart test showed >99% sensitivity/specificity on >200 human samples; aims for commercialization within 18 months.
- Target market: Barrett's esophagus affects 3-6M US patients; potential reimbursement $1,000–$3,000 per test.
- Transaction expected to close early January 2023, subject to Stella shareholder approval.
- Stella to receive 5% royalty on adjusted gross margin from commercialized IP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/868278/000149315222035948/0001493152-22-035948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/868278/000149315222035948/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-035948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer